MiMedx Group (MDXG) Delivers Record Full Year Revenue
MiMedx Group, Inc. (NASDAQ:MDXG) is one of the Best 52-Week Low Penny Stocks to Invest In. On February 25, MiMedx Group, Inc.
Mimedx Group Inc. (MDXG)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Trigran Investments Douglas T. Granat | 6,163,384 | $41,726,110 | -20% | 8.22% |
| 2. | Renaissance Technologies Jim Simons | 2,467,065 | $16,702,030 | +23% | 0.03% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,416,389 | $16,358,954 | +65% | 0.54% |
| 4. | Cannell Capital J. Carlo Cannell | 1,471,551 | $9,962,400 | -27% | 4.83% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,381,288 | $9,351,319 | +865% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.34 | 200,000 | $1,268,000.00 | 529,530 | 2025-05-02 | Filing | |
| $7.16 | 5,000 | $35,786.50 | 102,200 | 2023-11-21 | Filing | |
| $6.50 | 42,025 | $273,330.60 | 100,000 | 2023-06-23 | Filing | |
| $6.33 | 57,975 | $367,103.50 | 57,975 | 2023-06-22 | Filing | |
| $6.99 | 20,000 | $139,800.00 | 5,009,121 | 2016-05-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.42 | 58,300 | $432,329.48 | 236,982 | 2025-11-06 | Filing | |
| $8.04 | 1,759 | $14,142.36 | 309,077 | 2025-03-17 | Filing | |
| $7.89 | 20,366 | $160,687.74 | 440,178 | 2025-03-13 | Filing | |
| $7.89 | 34,230 | $270,074.70 | 460,544 | 2025-03-13 | Filing | |
| $7.89 | 4,106 | $32,396.34 | 310,836 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 609,112 | $2,405,992 | 0.02% | |
| 2. | 72,692 | $287,134 | 0.01% | |
| 3. | 20,300 | $80,185 | 0.03% | |
| 4. | 15,778 | $62,323 | 0.01% | |
| 5. | 15,850 | $61,498 | 0% |
News See All
11 Best 52-Week Low Penny Stocks to Invest In
On January 14, Eddie Ghabour, co-founder of Key Advisors Group LLC, appeared on a Schwab Network interview to discuss his bullish outlook for small-cap stocks.
Craig-Hallum Adjusts MiMedx Group, Inc. (MDXG) Outlook on CMS Coverage Guidance
TheFly reported on January 23 that Craig-Hallum analyst Chase Knickerbocker lowered the price target on MDXG to $10 from $13 and maintained a Buy rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2025 Operating and Financial Results Conference Call.
MiMedx Group, Inc. (MDXG) Partners with Vaporox for Advanced Wound Therapy
MiMedx Group, Inc. (NASDAQ:MDXG) is a biotechnology company based in Marietta, Georgia, specializing in regenerative biologics for advanced wound care and surgical recovery.
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. Welcome to the MiMedx Second Quarter 2025 Operating and Financial Results Conference Call.
MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. Welcome to the MIMEDX First Quarter 2025 Operating and Financial Results Conference Call.
MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call.
Hedge Fund Resource Center